Brightseed
Brightseed is a South San Francisco-based AI platform that maps natural compounds to biological mechanisms, helping health and life sciences companies discover, validate, and commercialize new ingredients. Its Forager engine and Hummingbird agentic AI serve 40+ enterprise partners across nutrition, pharma, and consumer health.
- Company typePrivate
- Founded2017
- HeadquartersSan Francisco, United States
- Headcount101–250
- GTM typeB2B
- OfferingSoftware
What Brightseed does
Brightseed is a bio- and AI-native innovation platform for health and life sciences companies, founded in 2017 and headquartered in South San Francisco. The company's Forager engine maps natural compounds to biological mechanisms and health pathways using a proprietary dataset that has expanded from 11 million to 21 million bioactives across 23 health territories, supported by over seven years of experimentally validated data. Hummingbird, launched in May 2026, extends the platform from discovery into development as an agentic AI product that accepts natural-language queries and returns actionable product evaluations in seconds. Both products are positioned as the world's first clinically-validated, continuous enterprise AI platform for health sciences innovation.
Brightseed operates a B2B platform-first subscription model targeting enterprise R&D and product development teams in consumer health, nutrition, pharmaceuticals, animal health, and cosmetics. The company serves more than 40 named industry partners including Danone, Haleon, L'Oréal, Nestlé Health Science, Ocean Spray, Opella, and Kallyope. Revenue streams include platform subscriptions (with a three-tier model covering subscriptions, data generation, and expert services), optional onboarding and enablement services, and B2B sales of proprietary clinically-validated ingredient products Bio Gut Core (digestive health) and BioMetaControl (metabolic health, positioned as a GLP-1 companion). Pricing is not publicly disclosed; contracts are sold on annual billing cycles via direct enterprise field sales.
The company has raised approximately $120.8 million in disclosed funding across six rounds between 2018 and 2023, with a $68 million round in May 2022 led by Temasek alongside AgFunder, S2G Investments, Continental Grain Company, Germin8 Ventures, and Lewis & Clark AgriFood. Brightseed is led by co-founder and CEO Jim Flatt, co-founder/CSO/CTO Lee Chae, and co-founder/Chairman Sofia Elizondo, with a headcount of 51-100 employees. Customers retain ownership of discoveries, ingredients, and IP developed using the platform, while Brightseed retains platform IP and commercializes its own ingredient portfolio.
Brightseed firmographics
Firmographics- Name
- Brightseed
- Legal name
- Brightseed, Inc.
- Website
- https://brightseedbio.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Brightseed is a South San Francisco-based AI platform that maps natural compounds to biological mechanisms, helping health and life sciences companies discover, validate, and commercialize new ingredients. Its Forager engine and Hummingbird agentic AI serve 40+ enterprise partners across nutrition, pharma, and consumer health.
- Ownership category
- akta.pro rank
Brightseed industry classification
Industry- Product category
- AI Bioactive Discovery Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medicinal and Botanical Manufacturing (325411), Scientific Research and Development Services (5417)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK)
- akta.pro secondary industries
- Healthy Aging & Cognitive Support Supplements (CRADAGAM), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
Keywords
Where Brightseed is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Brightseed business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Platform Subscriptions: Brightseed operates as a platform-first subscription business transitioning customers to recurring subscription model. The platform provides software-as-a-service (SaaS) and data-as-a-service to global health science clients.
- Three-Tier Pricing Model: Hummingbird product offered under three-tier pricing model covering subscriptions, data generation, and expert services. Optional services for onboarding and enablement are also available.
- Ingredient Sales: While primarily a platform company, Brightseed has commercialized two novel bioactives (NCT and NFT) in BioMetaControl supplement marketed as GLP-1 companion for metabolic health. The company engages in B2B sales of these specific ingredients.
- Professional Services: Optional services for onboarding and enablement complement the core platform subscription offering.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Three-tier pricing model including subscriptions, data generation, and expert services |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
Brightseed product offering
Product offeringCore offering
Brightseed operates a continuous, clinically-validated AI-powered health sciences innovation platform that combines the Forager™ AI discovery engine (mapping more than 11 million proprietary bioactives to biological mechanisms across 23 health territories) with the Hummingbird™ agentic AI product for development decision-making. The company sells platform subscriptions and data services to enterprise R&D teams in consumer health, nutrition, pharmaceuticals, animal health, and cosmetics, and also commercializes clinically-validated bioactive ingredients such as Bio Gut Core™, BioMetaControl™, and Bio Gut Fiber™.
Product overview
Brightseed operates as a continuous innovation platform combining deep science, cutting-edge AI, and proprietary bioactive data to transform how health science teams discover, validate, and commercialize new products. The platform follows a platform-plus-modules architecture anchored by Forager™ (AI-powered biological discovery engine with 11+ million bioactives across 23 health territories) extended by Hummingbird™ (agentic AI for development decision-making), supported by an Enterprise AI Platform integrating discovery, development, and commercialization. The portfolio includes commercialized bioactive ingredient products—Bio Gut Core™ for digestive health and BioMetaControl™ as a GLP-1 companion for metabolic health—alongside discovery tools (Bioactive Ingredient Finder, Bioactive Profiler) and Science-Backed Plant-Based Bioactives services. Brightseed serves B2B customers (innovation leaders, R&D teams, product development organizations) with software-as-a-service and data-as-a-service offerings under a recurring subscription model. Customers retain ownership of discoveries, ingredients, and IP developed using the platform.
Differentiator
Problem solved
Functional benefit
Brands
- Forager™: AI-powered biological discovery engine built on proprietary bioactive dataset spanning more than 11 million compounds across 23 health areas.
- Hummingbird™
- Bio Gut Core™
- BioMetaControl™
Products and services
- Forager™ Platform AI-powered biological discovery engine built on more than 11 million proprietary bioactives and hundreds of biological receptors across 23 health areas. Maps natural compounds to biological mechanisms and health pathways for enterprise customers in nutrition, wellness, agriculture, and pharmaceutical applications.
- Hummingbird™ Agentic AI product built on the Forager platform that enables nutrition and health companies to query natural compound data using natural language and receive answers in seconds. Helps teams evaluate, prioritize, and advance product opportunities ahead of major development investment.
- Enterprise AI Platform Continuous AI-powered health sciences innovation platform integrating discovery, development, and commercialization, built on proprietary bioactive datasets spanning more than 11 million natural compounds across 23 health territories and over seven years of experimentally validated data.
- Bio Gut Core™ Low-dose digestive health ingredient clinically proven to strengthen gut barrier function and reduce bloating and abdominal pain in three weeks. Developed using AI discovery from compounds found in plants like garlic and black pepper.
- BioMetaControl™ Nature-inspired GLP-1 companion ingredient for metabolic health containing clinically validated bioactives NCT (N-trans caffeoyltyramine) and NFT (N-trans feruloyltyramine). Demonstrated statistically significant improvements in glycemic control in adults with prediabetes in a peer-reviewed clinical trial.
- Bio Gut Fiber™
Quantifiable outcome
- A PhD scientist achieved in two weeks using Hummingbird what previously took six months
- +5 more outcomes
Companies that use Brightseed
Customer profileNamed customers10 records
Segments5 records
Ideal customer profiles3 records
Brightseed technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature5 records
Brightseed partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered minor and core.
- Evra IngredientsminorEvra Ingredients partnered with Brightseed to unlock next-generation natural ingredients with AI-powered discovery.
- HaleoncoreBrightseed and Haleon announced strategic collaboration to harness AI for small molecule discovery and human health innovation. The partnership focuses on using Brightseed's Forager AI platform to discover novel bioactive compounds for health applications.
- BotalysminorBrightseed and Botalys partnered to cultivate sustainably sourced bioactive botanicals for beauty, health and wellness sectors using AI-powered discovery.
- Ocean SpraycoreOcean Spray and Brightseed expanded their partnership to validate novel health benefits of bioactive compounds found in various cranberry varieties using Forager AI. The partnership began in 2021 and continues to leverage AI to decode and validate the total health potential of cranberries for consumer nutrition applications. AI analysis predicted four times more phytonutrients related to human health including terpenes in cognition and immunity areas.
- DanonecoreDanone is listed as a strategic partner collaborating with Brightseed on bioactive discovery and health science innovation initiatives.
- KallyopeminorKallyope is listed as a strategic partner in Brightseed's ecosystem for bioactive discovery.
- L'OréalcoreL'Oréal is listed as a strategic partner collaborating with Brightseed on bioactive discovery for beauty and wellness applications.
- Nestlé Health SciencecoreNestlé Health Science is listed as a strategic partner in Brightseed's innovation ecosystem.
- NutriQuestminorNutriQuest is listed as a strategic partner in Brightseed's bioactive discovery ecosystem.
- OpellaminorOpella is listed as a strategic partner in Brightseed's ecosystem for health science innovation.
- PharamviteminorPharamvite is listed as a strategic partner in Brightseed's innovation platform ecosystem.
- Almond Board of CaliforniaminorResearch partnership where Brightseed's AI was used as a case study to identify over 500 compounds in almonds, with 400 previously undiscovered, demonstrating AI's potential in food science compound discovery.
Scale indicators10 records
Recent moves6 records
Expansion highlights7 records
Brightseed competitors and assessment
Company assessmentDirect peers
- Atomwise: AI company focused on small molecule drug design using structure-based deep learning. Comparable AI-first discovery platform targeting pharma partners; less focused than Brightseed on nutrition and consumer health bioactives.
- Insilico Medicine: AI-native drug discovery company combining generative chemistry, biology, and clinical validation. Comparable to Brightseed's enterprise AI-for-bioactives model, though focused on small-molecule pharma rather than nutrition and consumer health.
- Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with machine learning. Directly comparable in using proprietary biological datasets and ML to accelerate discovery and reduce late-stage failures in life sciences.
- XtalPi: AI- and quantum physics-driven drug discovery and molecular simulation platform serving global pharma. Direct peer in AI-native scientific platforms for life sciences enterprise customers.
- Nuritas: AI-driven discovery platform for bioactive peptides in food, nutrition, and personal care. Closest direct peer to Brightseed: applies machine learning to natural compound libraries to identify health-benefiting peptides for CPG and supplement brands.
Broad incumbents
- Schrödinger: Computational chemistry and molecular simulation platform serving pharma, biotech, and materials science. Broad incumbent that, like Brightseed, sells subscription-based scientific software to enterprise R&D teams, but operates across a wider portfolio of industries.
Regional players
- Botalys: Belgium-based producer of sustainably cultivated premium botanical ingredients for health, beauty, and wellness brands. Already a Brightseed partnership counterparty, Botalys sits one layer upstream as a vertically specialized supplier rather than a discovery platform competitor.
Emerging players
- NotCo: AI-driven food technology company using proprietary models (Giuseppe AI) to formulate plant-based food and ingredient alternatives. Comparable in applying AI to discover and reformulate natural compounds for consumer CPG, but focused on plant-based foods rather than broad bioactives.
- Owkin: AI-for-biotech company that combines multimodal patient data with machine learning to accelerate drug discovery and development. Adjacent emerging player serving life sciences R&D with AI-driven intelligence, though anchored in clinical data rather than bioactives.
Others
- Culture Biosciences: Cloud biomanufacturing platform enabling CPG and synthetic biology companies to run fermentation and bioprocess R&D at scale. Ecosystem adjacent to Brightseed's bioactives value chain — supports the development and scale-up of bioactives that Brightseed discovers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Brightseed social profiles
Digital presenceBrightseed financial estimates
Financial estimateRevenue estimate
Valuation estimate
Brightseed leadership team
Management profileNumber of profiles
Profiles3 records
Brightseed funding detail
Funding detailFunding overview
Funding rounds6 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Brightseed M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Brightseed
What does Brightseed do?
Brightseed operates a continuous, clinically-validated AI-powered health sciences innovation platform that combines the Forager™ AI discovery engine (mapping more than 11 million proprietary bioactives to biological mechanisms across 23 health territories) with the Hummingbird™ agentic AI product for development decision-making. The company sells platform subscriptions and data services to enterprise R&D teams in consumer health, nutrition, pharmaceuticals, animal health, and cosmetics, and also commercializes clinically-validated bioactive ingredients such as Bio Gut Core™, BioMetaControl™, and Bio Gut Fiber™.
Is Brightseed a public or private company?
Brightseed is a private company. It is classified as venture growth investor backed and is currently operating.
When was Brightseed founded?
Brightseed was founded in 2017. It employs 101 to 250 people.
Where is Brightseed based?
Brightseed is headquartered in San Francisco, United States, in the North America region.
How does Brightseed make money?
Four revenue lines are on record. Platform Subscriptions are the primary driver. The others are three-Tier Pricing Model, ingredient Sales and professional Services.
Who are Brightseed's main competitors?
Direct peers on record are Atomwise, Insilico Medicine, Recursion Pharmaceuticals, XtalPi and Nuritas. Schrödinger is listed as a broad incumbent. Botalys is listed as a regional player. Emerging players are NotCo and Owkin. Culture Biosciences is listed as an others.
Does Brightseed have an API?
No public API is recorded for Brightseed.
What industry is Brightseed in?
Brightseed's product category is AI Bioactive Discovery Platform. Its primary akta.pro industry code is EUAAAIAK, Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives, with a secondary code of CRADAGAM, Healthy Aging & Cognitive Support Supplements. Its NAICS code is 541714 and its SIC code is 2833.